Chinese Alzheimer’s drug gets US approval for stateside trial

SHANGHAI: A Chinese drugmaker has received approval from the Food and Drug Administration to start clinical trials in the US for a breakthrough Alzheimer’s drug as it seeks global validation for the controversial therapy.

Shanghai Green Valley Pharmaceutical Co got clearance on April 8 for the US part of a global trial that seeks to enroll more than 2,000 patients with mild-to-moderate Alzheimer’s across North America, Europe and Asia, according to a company statement on Sunday (April 26).